WO2017129432A1

WO2017129432A1 - Sunscreen comprising tricyclodecanemethyl isononanoate

Info

Publication number: WO2017129432A1
Application number: PCT/EP2017/050777
Authority: WO
Inventors: Kathrin BORCHERS; Heike Lerg; Andreas Bleckmann; Janina ZIPPEL
Original assignee: Beiersdorf Ag
Priority date: 2016-01-27
Filing date: 2017-01-16
Publication date: 2017-08-03
Also published as: DE102016000800A1

Abstract

The invention relates to a cosmetic preparation containing a) tricyclodecanemethyl isononanoate and b) compound 1.

Description

Beiersdorf Aktiengesellschaft

Hamburg

description

Sunscreens with Tricyclodecanmethyl isononanoate The present invention relates to a cosmetic preparation containing

Tricyclodecanmethyl isononanoate (INCI: tricyclodecanemethyl isononanoate) and a precursor for 4- (tert-butyl) -4'-methoxydibenzoylmethane.

The trend away from the noble paleness to the "healthy, sporty brown skin" has been unbroken for years, to achieve this, people are putting their skin on the skin

Solar radiation, as this causes a pigmentation in the sense of melanin formation. However, the ultraviolet radiation of sunlight also has a damaging effect on the skin. In addition to the acute injury (sunburn), long-term damage such as an increased risk of developing skin cancer occurs due to excessive exposure to light from the UVB range (wavelength: 280-320 nm). The excessive action of UVB and UVA radiation (wavelength: 320-400 nm) also leads to a weakening of the elastic and collagen fibers of the connective tissue. This leads to numerous

phototoxic and photoallergic reactions and leads to premature aging of the skin.

To protect the skin, therefore, a number of sunscreen filter substances has been developed which can be used in cosmetic preparations. These UVA and UVB filters are in the form of positive lists in most industrialized countries such as Appendix 7 of the

Cosmetics Regulation summarized.

However, the large number of commercially available sunscreens must not disguise the fact that these prior art preparations contain a number of

Have disadvantages. In sunscreens, 4- (tert-butyl) -4'-methoxydibenzoylmethane is usually used as UV filter. However, this UV filter has the known disadvantage of not being particularly photostable on its own, but slowly decomposing under UV-B radiation in particular. If no further stabilizers (for example octocrylene) are added to the preparation, This decomposition process leads to a lower durability of the product as a whole and in particular to a decreasing with time UV-A protection.

Furthermore, 4- (tert-butyl) -4'-methoxydibenzoylmethane has the likewise known disadvantage of not being particularly soluble in cosmetic preparations, but of being able to extract it from the preparation relatively quickly. This also affects the durability and shelf life of the sunscreen, in particular their storage and temperature stability.

A relatively new approach to solve these problems of 4- (tert-butyl) -4'-methoxydibenzoylmethane in cosmetic preparations is to use chemical precursors (so-called

Precursor) of 4- (tert-butyl) -4'-methoxydibenzoylmethan use in the preparations. These then serve, since they transform under sunlight into the 4- (tert-butyl) -4'-methoxydibenzoylmethane, as starting material for a UV-protection which arises in the application. Such starting materials (precursors) are disclosed, for example, in WO2006 / 100225.

However, a disadvantage of the prior art is the fact that the precursors only relatively slowly and incompletely convert into the 4- (tert-butyl) -4'-methoxydibenzoylmethane to be formed. This is especially true for the following conversion reaction:

Compound 1 4- (tert-butyl) -4'-methoxydibenzoylmethane

It was therefore the object of the present invention to develop a cosmetic sunscreen containing compound 1, in which the photochemical conversion reaction is faster and more complete than in the formulations of the prior art.

Surprisingly, the object is achieved by a cosmetic preparation comprising a) tricyclodecanmethyl isononanoate (INCI: tricyclodecanemethyl isononanoate) and b)

Compound 1 The preparations according to the invention are distinguished by a significantly faster and more complete conversion of the precursor under UV light into 4- (tert-butyl) -4'-methoxydibenzoylmethane than is the case in the preparations of the prior art ,

Preparations as known from WO2006 / 060886 generally contain

Dimethicone. In comparison (see comparative experiment) to dimethicones, the conversion rate under comparable conditions in the presence of tricyclodecanmethyl isononanoate is significantly greater.

Moreover, the preparations according to the invention have the surprising advantage that they have a significantly lower yellowing before application (ie before the skin creamed with the preparation is exposed to sunlight) than is the case with preparations which contain an equivalent amount of (tert-butyl) -4'-methoxydiben- zoylmethane included. In addition, the preparations according to the invention lead to a significantly reduced textile stain (yellowing), as is the case with preparations which contain an equivalent amount of 4- (tert-butyl) -4'-methoxydibenzoylmethane, if the preparations before, during or advised to come into contact with textiles after use on the skin.

Although the prior art knows WO2006 / 100225, EP 2488537, EP2311844,

WO201 1/045389, US 2012/0230932, US 8945522, DE 10201 1 1 15285, WO 2013/045016, EP 2568953, FR 2857663, EP 1648849 and US 2013/0058879, but these documents could not point the way to the present invention.

It is advantageous according to the invention if the cosmetic preparation contains compound 1 in a concentration of 0.1 to 6% by weight, based on the total weight of the preparation.

It is preferred according to the invention if the cosmetic preparation contains compound 1 in a concentration of 1 to 4.75% by weight, based on the total weight of the preparation. It is advantageous for the purposes of the present invention if the preparation contains Tncyclodecanmethylisononanoat in a concentration of 0.1% to 15% by weight, based on the total weight of the preparation.

It is preferred for the purposes of the present invention, when the preparation

Tncyclodecanmethylisononanoat in a concentration of 1 to 10% by weight, based on the total weight of the preparation. According to the invention, the preparation according to the invention can advantageously contain one or more dialkyl adipates.

According to the invention, the total concentration of dialkyl adipates in the preparation is from 0.5 to 3% by weight, based on the total weight of the preparation (that is, if the preparation contains only one dialkyl adipate, this concentration corresponds to

Single concentration of this dialkyl adipate).

Embodiments of the present invention which are advantageous according to the invention are characterized in that one or more dialkyl adipates are selected from the group of the compounds dimethyl adipate, diethyl adipate, dipropyl adipate, diisopropyl adipate

Diisobutyl adipate, di-n-butyl adipate, di-2-ethylhexyl adipate and dicyclohexyl adipate.

According to the invention, it is particularly preferable to use di-n-butyl adipate as the dialkyl adipate. In a particularly preferred embodiment of the present invention, the dialkyl adipate used is exclusively di-n-butyl adipate. In this case, it is particularly advantageous according to the invention if the use concentration of di-n-butyl adipate is from 0.5 to 3% by weight, based on the total weight of the preparation. Embodiments of the present invention that are advantageous according to the invention are further characterized in that the preparation contains ethanol.

Such inventively advantageous embodiments of the present invention are characterized in that the preparation contains ethanol in a concentration of 0, 1 to 99% by weight, based on the total weight of the preparation. In this case, it is preferred according to the invention if the cosmetic preparation contains ethanol in a concentration of 2 to 60% by weight, based on the total weight of the preparation. It is also advantageous for the purposes of the present invention if the preparation contains C 12 -C 15 -alkyl benzoate.

In such a case, the embodiments according to the invention are characterized in that the preparation contains C12-C15 alkyl benzoate in a concentration of 1 to 20% by weight, based on the total weight of the preparation.

Embodiments which are advantageous according to the invention are characterized in that the preparation contains one or more dialkyl carbonates. In this case, these dialkyl adipates are preferably selected according to the invention from the group of compounds dicaprylyicarbonate dimethyl carbonate. Diethyl carbonate. Diisopropyl. Di-n-butyl carbonate. Particularly preferred according to the invention are the dialkyl carbonates diisopropyl carbonate and di-n-butyl carbonate.

According to the invention, the total concentration of dialkyl carbonates in the preparation is advantageously from 1 to 20% by weight, based on the total weight of the preparation (that is, if the preparation contains only one dialkyl carbonate, this concentration corresponds to the individual concentration of this dialkyl carbonate).

In addition, the preparation according to the invention may contain other lipophilic components, for example natural or synthetic oils, fats, waxes, as they are

commonly used in cosmetics.

It is inventively advantageous if the preparation of the invention is free of Dimethicone.

Embodiments of the present invention which are advantageous according to the invention are furthermore characterized in that the preparation comprises one or more compounds selected from the group of the compounds alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or or synthetic isoflavonoids, flavonoids, creatine, creatinine, taurine, β-alanine, panthenol, magnolol, honokiol,

Tocopheryl acetate, dihydroxyacetone; 8-hexadecene-1, 16-dicarboxylic acid, glycerylglycose, (2-hydroxyethyl) urea, vitamin E or its derivatives, hyaluronic acid and / or salts thereof and / or licochalcone A. Advantageous embodiments in the context of the present invention are further characterized in that the preparation contains one or more alkanediols from the group of compounds 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-octanediol, 1, 2-decanediol, 2 Methyl-1, 3-propanediol contains.

According to the invention, the total concentration of these alkanediols in the preparation is from 0.1 to 5% by weight, based on the total weight of the preparation (that is, if the preparation contains only one alkanediol, this concentration corresponds to

Single concentration of this alkanediol).

In addition, it is advantageous according to the invention if the preparation contains phenoxyethanol and / or ethylhexylglycerol. According to the invention, the total concentration of these substances in the

Preparation of 0.1 to 1% by weight, based on the total weight of the preparation (i.e., if the preparation contains only phenoxyethanol or ethylhexylglycerol, this concentration corresponds to the individual concentration of this substance). According to the invention, particularly advantageous embodiments of the present invention are characterized in that the preparation contains one or more UV filters which are selected from the group of the compounds 2-phenylbenzimidazole-5-sulfonic acid and / or salts thereof; Phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid salts; 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts; 4- (2-oxo-3-bomylidenemethyl) benzenesulfonic acid salts; 2-methyl-5- (2-oxo-3-bornylidenemethyl) sulfonic acid salts; 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol); 2- (2H-Benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [(trimethylsilyl) oxy] disiloxanyl] propyl] phenol ; 3- (4-methylbenzylidene) camphor; 3-benzylidenecamphor; ethylhexyl salicylate;

Terephthalidendicamphersulfonsäure; 2-ethylhexyl-2-cyano-3,3-diphenylacrylate; 2-ethylhexyl 4- (dimethylamino) benzoate; 4- (dimethylamino) benzoic acid amyl ester; Di (2-ethylhexyl) -4-methoxybenzalmalonate; 4-methoxycinnamate (2-ethylhexyl) ester; 4-methoxycinnamic acid isoamyl ester; 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl; 2-ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate; 3- (4- (2,2-ethoxycarbonylvinyl) phenoxy) propenyl) methoxysiloxane / dimethylsiloxane copolymer; 4- (tert-butyl) -4'-methoxydibenzoylmethane; 2- (4'-diethylamino-2'-hydroxybenzoyl) benzoate;

Dioctylbutylamidotriazone (INCI: diethylhexyl-butamidotriazone); 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) -imino] -6- (2-ethylhexyl) -imino-1,3,5-triazine with the CAS no. 288254-16-0); 2,4-Bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1, 3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine) ; 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2-ethylhexyl ester) (also: 2,4,6-tris [anilino] (p-carbo-2'-ethyl-1'-hexyloxy)] - 1, 3,5-triazine (INCI: ethylhexyl triazone); 2,4,6-tribiphenyl-4-yl-1,3,5-triazine ;

merocyanines; titanium dioxide; Zinc oxide.

It is inventively preferred if the preparation contains no 3- (4-methylbenzylidene) - camphor and 2-hydroxy-4-methoxybenzophenone (INCI: oxybenzone), that is free of these ingredients.

It is preferred according to the invention if the preparation according to the invention contains 2-phenylbenzimidazole-5-sulfonic acid salts.

In such a case, it is preferred according to the invention if the preparation contains 2-phenylbenzimidazole-5-sulfonic acid salts in a concentration of 1 to 4% by weight, based on the total weight of the preparation.

The use of sodium or potassium salts according to the invention is advantageous. Preference is also the use of 2-ethylhexyl 2-hydroxybenzoate (INCI: ethylhexyl salicylates).

Contains the preparation as salicylate 2-ethylhexyl 2-hydroxybenzoate (INCI: ethylhexyl

Salicylates), it is according to the invention advantageous to use this in a concentration of 3 to 5% by weight, based on the total weight of the preparation.

Contains the preparation as salicylate 3,3,5-trimethylcyclohexyl 2-hydroxybenzoate (INCI:

Homosalates), it is according to the invention advantageous to use this in a concentration of 3 to 10% by weight, based on the total weight of the preparation. If the preparation contains both salicylates, it is advantageous according to the invention 2-ethylhexyl 2-hydroxybenzoate (INCI: ethylhexyl salicylate) in a concentration of 2 to 5% by weight and 3,3,5-trimethylcyclohexyl 2-hydroxybenzoate (INCI: homosalates) in a concentration of 2 to 10% by weight, based in each case on the total weight of the preparation. Embodiments of the present invention which are advantageous according to the invention are characterized in that the preparation according to the invention comprises 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1, 3,5-triazine ( INCI: ethylhexyl triazone). According to the invention, it is advantageous if the preparation according to the invention comprises 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1, 3,5-triazine (INCI: ethylhexyl triazone ) in an amount of 2 to 5% by weight, based on the total weight of the preparation. It is advantageous for the purposes of the present invention, when the preparation of the invention 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1, 3rd , 5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazines).

In such a case, it is advantageous according to the invention if the preparation according to the invention comprises 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1, 3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazines) in an amount of 2 to 5% by weight, based on the total weight of the preparation.

It is advantageous according to the invention if the preparation is in the form of an emulsion. It is preferred according to the invention if the preparation is in the form of an O / W emulsion.

If the preparation according to the invention is in the form of an emulsion, then the

According to the invention advantageous embodiments characterized in that the

Preparation contains one or more emulsifiers selected from the group of the compounds glyceryl stearate citrate, glyceryl stearate (self-emulsifying), stearic acid,

Stearate salts, polyglyceryl-3-methylglycose distearate, sodium cetearylsulfate,

Sodium staroylglutamate, polyglyceryl-10 stearate, cetearyl alcohol, cetearyl sulfosuccinate, potassium cetyl phosphate. According to the invention, the total concentration of these emulsifiers in the

Preparation of 0.1 to 10% by weight, based on the total weight of the preparation (i.e., if the preparation contains only one emulsifier, this concentration corresponds to

Individual concentration of this emulsifier). The aqueous phase of the preparations according to the invention may advantageously contain customary cosmetic auxiliaries, such as, for example, isopropanol or polyols of low C number and their ethers, preferably propylene glycol, glycerol, electrolytes, self-tanning agents and in particular one or more thickening agents which can be advantageously selected from the group Silica, aluminum silicates, polysaccharides or their derivatives, for. As hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, particularly advantageous from the group of polyacrylates, preferably a polyacrylate from the group of so-called

Carbopols, for example Carbopols types 980, 981, 1382, 2984, 5984, each individually or in combination. Further thickeners which are advantageous according to the invention are those with the INCI Description Acrylates / C 10-30 Alkyl Acrylate Crosspolymer (eg Pemulen TR 1, Pemulen TR 2, Carbopol 1328 from NOVEON) and Aristoflex AVC (INCI: Ammonium

Acryloyldimethyltaurate / VP copolymer). It is preferred according to the invention, when the preparation contains xanthan gum, crosslinked acrylate / C10-C30 alkyl acrylate polymer and / or vinylpyrrolidone / hexadecene copolymer.

A content of glycerol of at least 5% by weight, based on the total weight of the preparation, is particularly advantageous according to the invention.

Embodiments of the present invention which are advantageous according to the invention are characterized in that the preparation is free of parabens, methylisothiazolinone,

Chloromethylisothiazolinone and DMDM hydantoin. It is furthermore advantageous for the purposes of the present invention if the preparation according to the invention comprises one or more perfume substances selected from the group of the compounds limonene, citral, linalool, alpha-isomethylionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexylacetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,1,4,4,6-hexamethyltetralin, adipic diester, alpha-amylcinnamaldehyde, alpha-methylionone, amyl C butylphenylmethylpropionalcinnamal, Amyl salicylate, amyl cinnamyl alcohol, aniseed alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate,

Bergamot oil, bitter orange oil, butylphenylmethylpropioal, cardamom oil, cedrol, cinnamal, cinnamyl alcohol, citronellylmethyl crotonate, citrus oil, coumarin, diethyl succinate, ethyllinalool, eugenol, Evernia furfuracea extract, Evernia prunastri extract, farnesol, guaiac wood oil, hexyl cinnamal, hexyl salicylate, hydroxycitronellal, lavender oil, lemone oil, linayl acetate .

Tangerine oil, menthyl PCA, methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethyl citrate and / or vanillin.

According to the invention, the preparation according to the invention advantageously contains film formers. Film formers for the purposes of the present invention are substances of different composition, which are characterized by the following property: If a film former is dissolved in water or other suitable solvents and the solution is then applied to the skin, it forms a film after the solvent has evaporated Essentially, it serves to fix the light filters on the skin, thus increasing the water resistance of the product.

It is particularly advantageous to use the film formers from the group of polymers based on polyvinylpyrrolidone (PVP).

to choose. Particularly preferred are copolymers of polyvinylpyrrolidone, for example, the PVP hexadecene copolymer and the PVP eicosene copolymer, which are among the

Trade names Antaron V216 and Antaron V220 are available from the GAF Chemicals Cooperation.

Also advantageous are other polymeric film formers, such as sodium polystyrene sulfonate, sold under the tradename Flexan 130 at National Starch and Chemical Corp. and / or polyisobutene, available from Rewo under the tradename Rewopal PIB1000. Other suitable polymers are e.g. Polyacrylamides (Seppigel 305), polyvinyl alcohols, PVP, PVP / VA copolymers, polyglycols, acrylate / octylacralimide copolymer (Dermacryl 79), acrylates copolymer (Epitex 66). Also advantageous is the use of hydrogenated castor oil Dimerdilinoleat (CAS 646054-62-8, INCI Hydrogenated Castor Oil Dimer Dilinoleate), which can be purchased from Kokyu Alcohol Kogyo under the name Risocast DA-H or PPG-3 Benzylethermyristat ( CAS 403517-45-3), which can be obtained under the trade name Crodamol STS from Croda Chemicals.

According to the invention, the use of the preparation according to the invention for protection against skin aging (in particular for protection against UV-induced skin aging) and as

Sunscreens.

Comparative test

With the following experiment, the effect according to the invention could be exemplified:

Recipe of the mixture

Compound 1 is dissolved in a concentration of 1: 10,000 in the solvent.

Table 1: Examination formulas

Instruments and software

1. Cuvette: 10mm High Precision Cell, Quartz SUPRASIL (Hellma Analytics)

2. UV absorption measuring device: Helias spectrophotometer (500 fiber light sphere) with

Double Monochromator and Photomultiplier (M.U.T. Aviation Technology, Wedel, Germany)

3. UV absorption meter lamp: LOT Lamp LSH102 (LOT Oriel, Darmstadt) with 75 W Xe-Arc Lamp

4. Suntester: Suntest CPS + (Atlas Material Testing Technology GmbH, Linsengericht, Germany) with water cooling unit for tempering the sample

5. Suntester lamp + filter: Solar Standard Filter acc. To COLIPA and DIN 67501 Ident-No .: 5607 7759

6. Software UV absorbance meter: Felix32 from PTI (Photon Technology International)

execution

1. Unirradiated sample:

o Measurement of the transmission in the wavelength range of 280-420nm, each in

1 nm increments, through the UV absorbance meter

o Dark current measurement (bg): measurement with blocked beam path o Reference intensity (lo): solvent in cuvette

o Sample (I): solvent + compound 1 in cuvette

o Three-fold measurements of the sample

o The extinction spectrum (absorption) is calculated as follows:

2nd Suntester:

o Irradiation of the samples in the Suntester 15 minutes with 600 W / m ²

3. Irradiated sample:

o repetition point 1

4. Integral of the curves before (FE _before ) and after (FE _naCh ) the irradiation in the UVA range 320-400nm

o increase in absorption after irradiation: FE _before -

AFE

Result

Table 2: Absorption increase of compound 1 in tricyclodecanmethyl isononanoate or dimethicone

Conclusion:

In Tricyclodecanmethylisononanoat significantly more molecules of the compound 1 are rearranged in 4- (tert-butyl) -4'-methoxydibenzoylmethan under irradiation as in Dimethicone.

Examples

The following examples are intended to illustrate the present invention without limiting it. All amounts, proportions and percentages are, unless stated otherwise, based on the weight and the total amount or on the total weight of the preparations.

Example 1 Example 2 Example 3 Example 4 Example 5

IIMPI

ΓΪΊ [%] m [%] m [%] m [%] m [%]

Butyl methoxydibenzoylmethane 2.50 0.50 1.50 5.00 5.00

Connection 1 2.50 4.50 3.50 5.00 5.00

Bis-Ethylhexyloxyphenol Methoxyphenyl Triazines 3.50 3.50 0.50 0.50 0.50

Phenylbenzimidazole sulfonic acid 1.00 1.00 1.00 1.00 1.00

Ethylhexyl salicylates 5.00 5.00 5.00 5.00 5.00

Titanium dioxides (nano) + trimethoxycaprylylsilanes 6.00 4.00

Octocrylene 5.00 5.00 5.00 10.00 10.00

Homosalats 10.00 10.00 10.00 10.00 10.00

Trisodium EDTA 1.00 1.00 1.00 1.00 1.00

Cetearyl Alcohol 1.00 0.50

Myristyl Myristate 1.00 1.00

Stearyl Alcohol 0.50

Xanthan Gum 0.40 0.40 0.40

Acrylates / C 10-30 Alkyl Acrylate Crosspolymer 0.05 0.40 0.40

Carbomer 0.20

Alcohol Denat. + Aqua 4.00 4.00 6.00 6.00 6.00

Methyl paraben 0.30 0.30 0.30 0.30

Phenoxyethanol 0.60 0.60 0.60 0.60 0.60

Pentylene Glycol 1.00 1.00 1.00

Methylpropanediol 3.00 3.00

Ethylhexylglycerol 0.50 0.50 0.50

Citric Acid 0.30

Sodium Citrate 0.10

Sodium Hydroxide 0.30 0.35 0.32 0.30 0.30

Glycerine 3.00 9.00 1.00 9.00 9.00

Butylene glycol 6.00

Perfume 0.40 0.60 0.30 0.30

VP / hexadecene copolymer 0.50 0.50 0.50 0.50

Silica dimethyl silylates 0.50 0.50

Tapioca Starch 1.00

Sodium Cetearyl Sulfate 0.15 Glyceryl Stearate SE 1.00

Glyceryl Stearate Citrate 2.00

Ceteareth-20 1.00 1.00

Sodium Stearoyl Glutamate 0.40

Glyceryl Stearate 1.00

Hydrogenated Coco-Glycerides 1.00 1.00

C18-36 Acid triglycerides 0.50 0.50

C18-38 alkyl hydroxystearoyl stearate 0.50

Butylene Glycol Dicaprylate / Dicaprate 3.00

C12-15 Alkyl Benzoate 3.00 3.00 3.00 3.00 3.00

Tricyclodecanmethylisononanoate 5.00 10.00 5.00 8.00 5.00

Dibutyl adipate 3.00 3.00

Isopropyl Palmitate 3.00 2.00

Aqua 31.30 29.75 41.68 29.10 31.10

Claims

claims

1. Cosmetic preparation containing

a) Tricyclodecanmethyl isononanoate and

b)

Connection 1

2. Cosmetic preparation containing compound 1 in a concentration of 0.1 to 6% by weight, based on the total weight of the preparation.

3. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains tricyclodecanmethyl isononanoate in a concentration of 0.1 to 15% by weight, based on the total weight of the preparation.

4. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains one or more dialkyl adipates.

5. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains as dialkyl adipate di-n-butyl adipate.

6. Cosmetic preparation according to one of the preceding claims, characterized

characterized in that the preparation contains ethanol.

7. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains ethanol in a concentration of 0.1 to 99% by weight, based on the total weight of the preparation.

8. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains C12-C15 alkyl benzoate.

9. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains C12-C15 alkyl benzoate in a concentration of 1 to 20% by weight, based on the total weight of the preparation.

10. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains one or more dialkyl carbonates.

1 1. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains one or more compounds selected from the group of the compounds alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic isoflavotenoids, flavonoids, creatine , Creatinine, taurine, β-alanine, panthenol, magnolol, honokiol, tocopheryl acetate, dihydroxyacetone; 8-hexadecene-1, 16-dicarboxylic acid, glycerylglycose, (2-hydroxyethyl) urea, vitamin E or its derivatives, hyaluronic acid and / or salts thereof and / or licochalcone A contains.

12. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains one or more alkanediols from the group of the compounds 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-octanediol, 1, 2-decanediol, 2-methyl-

1, 3-propanediol.

13. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains phenoxyethanol and / or ethylhexylglycerol.

14. Cosmetic preparation according to one of the preceding claims, characterized

characterized in that the preparation contains one or more UV filters which are selected from the group of the compounds 2-phenylbenzimidazole-5-sulphonic acid and / or salts thereof; Phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid salts; 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its salts; 4- (2-oxo-3-bornylidenemethyl) benzenesulfonic acid; 2-methyl-5- (2-oxo-3-bomididenemethyl) sulfonic acid salts; 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol); 2- (2H-Benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [(trimethylsilyl) oxy] disiloxanyl] propyl] phenol ; 3- (4-methylbenzylidene) camphor; 3-benzylidenecamphor; ethylhexyl salicylate;

Terephthalidendicamphersulfonsäure; 2-ethylhexyl-2-cyano-3,3-diphenylacrylate; 2-ethylhexyl 4- (dimethylamino) benzoate; 4- (dimethylamino) benzoic acid amyl ester; 4-Methoxybenzalmalon-säuredi (2-ethylhexyl) ester; 2-ethylhexyl 4-methoxycinnamate; Isoamyl 4-methoxycinnamate; 2-hydroxy-4-methoxybenzophenone,

2-hydroxy-4-methoxy-4'-methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl; 2-ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate;

3- (4- (2,2-bisethoxycarbonylvinyl) phenoxy) propenyl) methoxysiloxane / dimethylsiloxane copolymer; 4- (tert-butyl) -4'-methoxydibenzoylmethane; Hexyl 2- (4'-diethylamino-2'-hydroxybenzoyl) benzoate; Dioctylbutylamidotriazone (INCI: diethylhexylbutamidotriazone); 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) -imino] -6- (2-ethylhexyl) -imino-1,3,5-triazine having the (CAS No 288254-16-0); 2,4-Bis - {[4- (2-ethyl-hexyl-oxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1, 3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine); 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester) (also: 2,4,6-tris [anilino] (p-carbo-2'-ethyl-1'-hexyloxy)] - 1, 3,5-triazine (INCI: ethylhexyl triazone); 2,4,6-tribiphenyl-4-yl-1,3,5-triazine Merocyanines; titanium dioxide; zinc oxide.

15. Cosmetic preparation according to one of the preceding claims, characterized

characterized in that the preparation is in the form of an emulsion.

16. Cosmetic preparation according to one of the preceding claims, characterized in that the preparation is in the form of an O / W emulsion.

17. Cosmetic preparation according to one of the preceding claims, characterized

in that the preparation contains one or more emulsifiers selected from the group of the compounds glyceryl stearate citrate, glyceryl stearate (self-emulsifying), stearic acid, stearate salts, polyglyceryl-3-methylglycose distearate, sodium ceplearyl sulphate, sodium staroylglutamate, polyglyceryl-10-stearate, cetearyl alcohol, cetearyl sulphosuccinate, potassium cetyl phosphate ,

18. Cosmetic preparation according to one of the preceding claims, characterized

characterized in that the preparation is free of Dimethicone.